Belgian-Dutch immunology company argenx (ARGX.BR), will buy Forte Biosciences (FBRX.O), to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
Argenx will pay $77 a share in cash, valuing the U.S. drug developer at about $2.2 billion, in a deal that gives it a first-in-class anti-CD122 antibody that has shown early promise in vitiligo and celiac disease.
By Reuters
Source: reuters.com
Stefan Doboczky has served as Chairman of the Board of Directors of Hovione since 2024, where he has been instrumental in shaping the company’s strategy and vision. He will step down as Chairman upon assuming the role of Chief Executive Officer.
CordenPharma is investing €80 million at its Caponago, Italy, site, adding a new facility and fill-finish lines to lift sterile injectable capacity to 500 million units/year, backed by shareholder Astorg. The expansion involves two key components to augment manufacturing capacity for sterile injectable drug products.
The investment will reinforce the Bend site as a center of excellence for particle engineering and bioavailability enhancement and create a global manufacturing hub for commercial spray-drying. Lonza will offer a full range of spray-dried dispersion (SDD) capacity to support customers across both clinical and commercial programs.
